UBS Reiterates Rating on CLDX $CLDX
Key Points
- UBS now rates Celldex Therapeutics, Inc. ($CLDX) "buy" with a $45.00 target.
- The Street's average $CLDX price target is $57.53 (Strong Buy).
- $CLDX last traded around $30.54.
UBS reiterated its rating on Celldex Therapeutics, Inc. ($CLDX) to a "buy" rating, with a price target of $45.00 in a recent research note.
Celldex Therapeutics, Inc. ($CLDX) Stock
Celldex Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.